EXECUTIVE MANAGEMENT
Pierre Attali, MD
Chief Executive Officer
Email : p.attali@urogene.com
Pierre Attali, MD, MSc, spent 11 years in academic hospitals as specialist in liver diseases and gastroenterology before joining Synthelabo (now sanofi-aventis) where he finally headed the Clinical Research Department. He has been closely involved in all phases of product development, being in charge of clinical strategy and worldwide clinical operations. He thus headed the development of important products at Synthelabo such as Zolpidem, Alfuzosine and Mizolastine.
After the merger with Sanofi, he co-founded and managed as CEO a CRO specialised in oncology. After merging this company with a German CRO in 2002, he was appointed CEO of Molecular Engines Laboratories (MEL), a French biotech company dedicated to oncology. He moved MEL to a drug development oriented company and merged it with CEREP (Euronext : CER).
He is board member of Quantificare, and President and co-founder of GETNA, a cooperative oncology group.
Hugues Bienaymé, PhD
Managing Director & CSO
Email : h.bienayme@urogene.com
Hugues Bienaymé owns a PhD in organic chemistry. He spent 10 years with Rhône-Poulenc (now sanofi-aventis), heading research groups in combinatorial and medicinal chemistry.
From 2001 to 2003 he founded and managed a combinatorial/medicinal chemistry company (Chrysalon). Since 2004, he is responsible for research and preclinical activities at Urogene. He was awarded several distinctions, including the Industrial Prize of the French National Chemical Society (2003); the Aventis-Institut de France Foundation prize (2001) ; the French Ministry of Education and Research start-up company prize (2000 & 2001) ; the Prize of the Organic Chemistry Division (French National Chemical Society, 1998). He is author, or co-author, of 39 peer-reviewed articles and 18 patents.
SUPERVISORY BOARD
Christian Grenier
Chairman of the Board.
He occupied top managerial positions with RP/Aventis over the last 15 years. He was previously consultant with McKinsey & Co.
Pr Pierre Teillac
Urological surgeon at the Hospital Saint-Louis, Paris.
Secretary General of the European Association of Urology.
Gilles Schang
Senior Investment Manager for Société Générale Asset Management (SGAM, France).
Claude Stoufs
Senior Investment Manager for Capricorn Venture Partners (Belgium).
INVESTORS
UroGene is a privately-held company and has raised over 15 M€ from leading venture capitalists since inception in 1998.
Main investors:
Société Générale Asset Management
Capricorn Venture Partners
Nuage Ltd
CDC Entreprises - FCJE
Genavent
OSEO-ANVAR
